Related Experiment Video

Updated: Jun 19, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

What is the optimal treatment strategy for T1 bladder tumors?

Marko Babjuk

    European Urology
    |October 23, 2009
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
    08:43

    An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

    Published on: July 28, 2012

    A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
    06:23

    A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

    Published on: January 12, 2017

    Related Experiment Videos

    Last Updated: Jun 19, 2026

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
    11:02

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

    Published on: October 30, 2013

    An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
    08:43

    An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

    Published on: July 28, 2012

    A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
    06:23

    A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

    Published on: January 12, 2017

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Urinary Tract Calculi VI: Surgical Management01:25

    Urinary Tract Calculi VI: Surgical Management

    Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...

    Articles linked to this work by shared authors, journal, and citation graph.

    Urinary Amino Acid Profiling as a Non-invasive Diagnostic and Risk Stratification Tool in Prostate Cancer.

    In vivo (Athens, Greece)·2026

    Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group.

    European urology oncology·2025

    Towards Defining Follow-up Strategies for Patients with Primary Intermediate-risk Non-muscle-invasive Bladder Cancer.

    European urology oncology·2025

    The Importance of Being Grade 3: A Plea for a Three-tier Hybrid Classification System for Grade in Primary Non-muscle-invasive Bladder Cancer.

    European urology·2024

    Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.

    European urology·2024

    Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer.

    BJU international·2024

    Why Look Further When the Solution Is in Front of You - or Is It? The Value of Confirmatory PSA in Prostate Cancer Screening.

    European urology·2026

    Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial.

    European urology·2026

    Hereditary Renal Cancer Syndromes: Redefining Clinical Management in the Era of Precision Medicine.

    European urology·2026

    PSMA Radio-guided Surgery to Identify Lymph Node Metastases in Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Phase 2 Prospective Study.

    European urology·2026

    EORTC 2238 DE-ESCALATE: Revisiting Intermittent Maximal Androgen Blockade in Metastatic Hormone-sensitive Prostate Cancer.

    European urology·2026

    Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis.

    European urology·2026

    Delayed Diabetes Treatment and Persistent Hyperglycemia among Individuals with Schizophrenia: a Nationwide Register-Based Study.

    Schizophrenia bulletin·2026

    Evaluating Combined Sorafenib and Gemcitabine Treatment in HepG2 Cells and a NOD/SCID Mouse Xenograft Model: A Pilot Study.

    Journal of visualized experiments : JoVE·2026

    An Engineering-Editable Hybrid Membrane‑Camouflaged DNA Origami Drug Enables Checkpoint Blockade and Immune Activation for Triple-Negative Breast Cancer Immunotherapy.

    Angewandte Chemie (International ed. in English)·2026

    Chemotherapy-Activated GSK3β-DNMT1 Signaling Upregulates CD47 to Evade Macrophage Phagocytosis and Drive Temozolomide Resistance in Glioblastoma.

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

    Restoration of m6A-Modified circPSMB1 Suppresses Chordoma Progression and Enables Local Nanotherapeutic Intervention.

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

    Dietary-Derived Corchorus olitorius L. Extract Suppresses KRAS-Mutant Pancreatic Cancer by Activating Ferritinophagy-Dependent Ferroptosis.

    Journal of food science·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us